A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis ...
Oct 21, 2021
0
0
Cancer patients are at increased risk of SARS-CoV-2 infection and severe COVID-19 courses. Coronavirus vaccination is generally recommended for cancer patients, but so far little is known about how well they respond to the ...
Oct 1, 2021
0
44
A clinical trial led by researchers at City of Hope, a world-renowned cancer research and treatment organization, showed that patients over 65 receiving chemotherapy experienced significantly fewer treatment-related side ...
Sep 30, 2021
0
29
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.
Sep 23, 2021
0
9
Prostate-specific membrane antigen, or PSMA, -targeted PET imaging for prostate cancer has been a breakthrough diagnosis tool in locating prostate cancer tumors for more precise treatment. The new imaging technique can locate ...
Sep 16, 2021
0
31
(HealthDay)—Allogeneic blood or marrow transplantation (BMT) recipients have experienced a reduction in late mortality over time, according to a study published online Sept. 9 in JAMA Oncology.
Sep 14, 2021
0
4
A Phase 2 trial led by City of Hope, a world-renowned research and treatment center for cancer and diabetes, suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care ...
Aug 26, 2021
0
48
A new study published in JAMA Oncology by Winship Cancer Institute of Emory University's Michael H. Chung, MD, MPH, and colleagues, finds that loop electrosurgical procedure (LEEP) is more effective than cryotherapy in clearing ...
Aug 26, 2021
0
77
A combination of metformin and chemoradiation in patients with locally advanced non-small cell lung cancer (LA-NSCLC) was not found to add survival benefit in the NRG Oncology clinical trial NRG-LU001. These results were ...
Aug 24, 2021
0
283
(HealthDay)—The seropositivity rate among patients with cancer remains high four months after the second dose of the COVID-19 vaccine, according to a research letter published online Aug. 11 in JAMA Oncology.
Aug 23, 2021
0
2
